Discovering Our Lead Compound
Based on overall chemical stability, efficacy, negligible cardiovascular effects, and onset profiles, ATLX-0199 (D-Cystine diME) was selected as the lead compound for clinical development, with back-up compounds available. ATLX-0199 safely stimulates opioid-depressed respiratory drive without interfering with opioid-induced analgesia.
Platform / Pipeline
Lead compound ATLX-0199 ready for clinical development, with platform molecules available